On June 7, 2022, the Federal Trade Commission (FTC) launched an inquiry into six of the largest pharmacy benefit managers (PBMs). The FTC requested these PBMs provide information on their business practices to the FTC including how PBMs: (1) charge fees and clawbacks to unaffiliated pharmacies; (2) employ methods to steer patients towards PBM owned pharmacies; (3) unfairly audit independent pharmacies; (4) complicate methods for determining pharmacy reimbursements; (5) employ prior authorization policies and other administrative restrictions; (6) use specialty drug lists and specialty drug policies; and (7) use rebates and fees from drug manufacturers in formulary designs and how this impacts the cost of prescription drugs. Read more about the FTC inquiry here.
Last Updated on June 15, 2022 by Aimed Alliance
